Intensity of adjuvant chemotherapy regimens and grade III-V toxicities among elderly stage III colon cancer patients.

[1]  F. Retornaz,et al.  PRODIGE 34-FFCD 1402-ADAGE: Adjuvant chemotherapy in elderly patients with resected stage III colon cancer: A randomized phase 3 trial. , 2016, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[2]  C. Tournigand,et al.  Chronological Age and Risk of Chemotherapy Nonfeasibility: A Real-Life Cohort Study of 153 Stage II or III Colorectal Cancer Patients Given Adjuvant-modified FOLFOX6 , 2015, American journal of clinical oncology.

[3]  S. Hughes,et al.  The impact of low-grade toxicity in older people with cancer undergoing chemotherapy , 2014, British Journal of Cancer.

[4]  Sunita Ghosh,et al.  CAPOX associated with toxicities of higher grade but improved disease-free survival when compared with FOLFOX in the adjuvant treatment of stage III colon cancer. , 2014, Clinical colorectal cancer.

[5]  Sunita Ghosh,et al.  Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience. , 2014, Clinical colorectal cancer.

[6]  I. Browner,et al.  Refining the chemotherapy approach for older patients with colon cancer. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  V. Lemmens,et al.  Administration of adjuvant oxaliplatin to patients with stage III colon cancer is affected by age and hospital , 2014, Acta oncologica.

[8]  A. Thiébaut,et al.  Elderly patients with colorectal cancer: treatment modalities and survival in France. National data from the ThInDiT cohort study. , 2014, European journal of cancer.

[9]  C. Lepage,et al.  Toxicity of Oxaliplatin Plus Fluorouracil/Leucovorin Adjuvant Chemotherapy in Elderly Patients with Stage III Colon Cancer: A Population-Based Study , 2014, Annals of Surgical Oncology.

[10]  V. Lemmens,et al.  Reduced risk of distant recurrence after adjuvant chemotherapy in patients with stage III colon cancer aged 75 years or older. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  V. Lemmens,et al.  Chemotherapy-induced neuropathy and its association with quality of life among 2- to 11-year colorectal cancer survivors: results from the population-based PROFILES registry. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  J. Meyerhardt,et al.  Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  O. Bouché,et al.  Geriatric factors predict chemotherapy feasibility: ancillary results of FFCD 2001-02 phase III study in first-line chemotherapy for metastatic colorectal cancer in elderly patients. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  M. Janssen-Heijnen,et al.  Treatment and complications in elderly stage III colon cancer patients in the Netherlands. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[15]  H. Wasan,et al.  Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial , 2012, British Journal of Cancer.

[16]  K. Kahn,et al.  Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  G. Lyman,et al.  Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score , 2012, Cancer.

[18]  W. Scheithauer,et al.  Capecitabine versus 5-fluorouracil/folinic acid as adjuvant therapy for stage III colon cancer: final results from the X-ACT trial with analysis by age and preliminary evidence of a pharmacodynamic marker of efficacy. , 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

[19]  C. Punt,et al.  Adjuvant chemotherapy in stage III colon cancer: Guideline implementation, patterns of use and outcomes in daily practice in The Netherlands , 2012, Acta oncologica.

[20]  N. Petrelli,et al.  Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  S. Culine,et al.  Comprehensive geriatric assessment in the decision-making process in elderly patients with cancer: ELCAPA study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  Supriya G Mohile,et al.  Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  J. Meyerhardt,et al.  Patterns of adjuvant chemotherapy use in a population-based cohort of patients with resected stage II or III colon cancer. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  M. Parmar,et al.  Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial , 2011, The Lancet.

[25]  K. Kahn,et al.  Adjuvant chemotherapy use and adverse events among older patients with stage III colon cancer. , 2010, JAMA.

[26]  T. Hickish,et al.  Improved overall survival with oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment in stage II or III colon cancer in the MOSAIC trial. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  A. Meade,et al.  Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience , 2009, British Journal of Cancer.

[28]  N. Wolmark,et al.  Severe enteropathy among patients with stage II/III colon cancer treated on a randomized trial of bolus 5‐fluorouracil/leucovorin plus or minus oxaliplatin , 2007, Cancer.

[29]  J. Kopec,et al.  Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[30]  C. Tournigand,et al.  Pooled analysis of safety and efficacy of oxaliplatin plus fluorouracil/leucovorin administered bimonthly in elderly patients with colorectal cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  B. Reigner,et al.  Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  Markus Abt,et al.  Capecitabine as adjuvant treatment for stage III colon cancer. , 2005, The New England journal of medicine.

[33]  W. Scheithauer,et al.  Oral capecitabine as an alternative to i.v. 5-fluorouracil-based adjuvant therapy for colon cancer: safety results of a randomized, phase III trial. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.